Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. [electronic resource]
Producer: 20101217Description: 1386-9 p. digitalISSN:- 1539-2864
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Anticoagulants -- administration & dosage
- Aspirin -- administration & dosage
- Bevacizumab
- Choroidal Neovascularization -- drug therapy
- Clopidogrel
- Eye Hemorrhage -- epidemiology
- Female
- Humans
- Incidence
- Intravitreal Injections
- Macular Degeneration -- drug therapy
- Male
- Middle Aged
- Platelet Aggregation Inhibitors -- administration & dosage
- Ranibizumab
- Retrospective Studies
- Risk Factors
- Ticlopidine -- administration & dosage
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Warfarin -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.